Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases

This publication has 19 references indexed in Scilit:

• Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo
  Molecular and Cellular Endocrinology, 2006
• Targeting Breast and Prostate Cancers Through Their Hormone Receptors1
  Biology of Reproduction, 2005
• Targeted Ablation of Prostate Carcinoma Cells Through LH Receptor Using Hecate-CGβ Conjugate: Functional Characteristic and Molecular Mechanism of Cell Death Pathway
  Experimental Biology and Medicine, 2005
• A Novel Targeted Therapy of Leydig and Granulosa Cell Tumors through the Luteinizing Hormone Receptor Using a Hecate-Chorionic Gonadotropin β Conjugate in Transgenic Mice
  Neoplasia, 2005
• Membrane Disrupting Lytic Peptides for Cancer Treatments
  Current Pharmaceutical Design, 2004
• Cancer Statistics, 2003
  CA: A Cancer Journal for Clinicians, 2003
• Effects of a Lytic Peptide Conjugated to β hCG on Ovarian Cancer: Studies in Vitro and in Vivo
  Gynecologic Oncology, 2002
• Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors
  The Prostate, 2001
• Phylogenetic Perspectives in Innate Immunity
  Science, 1999
• Preclinical models for the evaluation of targeted therapies of metastatic disease
  Cell Biochemistry and Biophysics, 1994